TrialsgramBetaRCTs are beautiful
AHA Scientific Sessions 2026Präsentiert Sa., 7. Nov. · 15:45 GMT-6LBS.03 Late-breaking Science: Hot Topics in CVD PreventionAlle Studien (Late-Breaking Science) →

Ez-PAVE

2026

Ez-PAVE: Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease, prespecified second randomisation

In patients with atherosclerotic cardiovascular disease, initial statin-ezetimibe combination therapy did not reduce the 3-year composite of cardiovascular death, myocardial infarction, stroke, revascularisation or hospitalisation for unstable angina compared with statin monotherapy.

Ergebnis

Wirksamkeit: Cardiovascular outcomes within 3 yearshazard ratio 1,07 (95%-KI 0,83-1,37) · P = 0,596

Unter 1 spricht für initial statin-ezetimibe combination therapy, über 1 für statin monotherapy.

Ereignisraten
Absolute Differenz
0,6 Punkte

Die absolute Differenz ist aus den Ereignisraten abgeleitet.

Außerdem berichtet: Median LDL-C during follow-up was 53 mg/dL (interquartile range 45-62) vs 62 mg/dL (interquartile range 53-74) with intensive targeting, and 63 mg/dL (interquartile range 55-73) vs 70 mg/dL (interquartile range 62-81) with conventional targeting. The safety end points were similar between the groups.

Originalpublikation
Unterthema
Ezetimibe combination
Design
Open-label 2-by-2 factorial randomised trial in Korea (Yonsei University). First randomisation: LDL-C target below 55 versus below 70 mg/dL. The prespecified second randomisation, presented here: statin-ezetimibe combination versus statin monotherapy
Eingeschlossen
3.048 Patienten
Quelle
Lee SH, Byun YS, et al. Circulation. 2026; published online 7 November.doi 10.1161/CIRCULATIONAHA.126.083811

Diskussion & Kritik

Starting with statin-ezetimibe combination therapy lowered LDL-C during follow-up under both targeting strategies but did not reduce the primary composite endpoint compared with statin monotherapy. The composite includes any revascularisation and hospitalisation for unstable angina, so softer components may weigh on the total, and the abstract does not break the endpoint down into its components. Follow-up is three years, which may be too short to show a difference in hard outcomes from a modest gap in LDL-C. The abstract reports safety only as similar between groups and gives no figures.

In Podcasts besprochen